Cellebrite DI (NASDAQ:CLBT) Reaches New 12-Month Low – What’s Next?

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) reached a new 52-week low during trading on Friday . The stock traded as low as $11.30 and last traded at $11.6640, with a volume of 947531 shares changing hands. The stock had previously closed at $12.41.

Analyst Upgrades and Downgrades

CLBT has been the subject of several analyst reports. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Price Performance

The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 35.58, a P/E/G ratio of 1.69 and a beta of 1.28. The company’s fifty day moving average price is $14.00 and its 200-day moving average price is $16.46.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The firm had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. On average, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in Cellebrite DI by 45.1% in the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after buying an additional 1,238 shares during the last quarter. Invesco Ltd. boosted its position in Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after buying an additional 43,041 shares during the last quarter. Corient Private Wealth LLC boosted its position in Cellebrite DI by 29.8% in the 4th quarter. Corient Private Wealth LLC now owns 107,145 shares of the company’s stock worth $1,932,000 after purchasing an additional 24,596 shares in the last quarter. Vident Advisory LLC boosted its position in Cellebrite DI by 7.1% in the 4th quarter. Vident Advisory LLC now owns 50,887 shares of the company’s stock worth $917,000 after purchasing an additional 3,372 shares in the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in Cellebrite DI in the 4th quarter worth approximately $1,300,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.